Finally, an anti-CD20 antibody meeting endpoints in randomized trials
Comment on: “Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus” Richard A. Furie et al. NEJM March 2026 Commented by: Karoline Lerang, Department of Rheumatology, Oslo University Hospital- NORWAY Nearly 15 years after the EXPLORER and LUNAR trials failed in systemic lupus erythematosus (SLE), obinutuzumab—a type II anti-CD20 antibody developed by Roche—has succeeded, meeting … Read more